[
  {
    "ts": null,
    "headline": "Baxter Q2 Preview: Can Core Segments Deliver Another Solid Quarter?",
    "summary": "BAX aims for modest Q2 growth as core segments build on Q1 momentum and margin gains stabilize after recent recovery.",
    "url": "https://finnhub.io/api/news?id=be414a05cd245f2ffec2bc629e3c14694b0e6b8f79a13feb344b7da21e2bfee8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753720860,
      "headline": "Baxter Q2 Preview: Can Core Segments Deliver Another Solid Quarter?",
      "id": 136108675,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "BAX aims for modest Q2 growth as core segments build on Q1 momentum and margin gains stabilize after recent recovery.",
      "url": "https://finnhub.io/api/news?id=be414a05cd245f2ffec2bc629e3c14694b0e6b8f79a13feb344b7da21e2bfee8"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy, Sell, or Hold GE Healthcare Before Q2 Earnings?",
    "summary": "GEHC leans on Imaging and PDx strength for Q2, but tariff headwinds and margin pressures could test investor confidence.",
    "url": "https://finnhub.io/api/news?id=195d64e36762578205a15c77dbbf526438a7bd626c1646d203bab319c69c93e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753720680,
      "headline": "Should You Buy, Sell, or Hold GE Healthcare Before Q2 Earnings?",
      "id": 136108677,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "GEHC leans on Imaging and PDx strength for Q2, but tariff headwinds and margin pressures could test investor confidence.",
      "url": "https://finnhub.io/api/news?id=195d64e36762578205a15c77dbbf526438a7bd626c1646d203bab319c69c93e2"
    }
  },
  {
    "ts": null,
    "headline": "RVTY Posts Q2 Earnings & Sales Beat, Raises '25 Sales View",
    "summary": "Revvity's second-quarter results showcase strong growth in its Diagnostics business, along with recovery in Life Sciences segmental sales.",
    "url": "https://finnhub.io/api/news?id=ae18b0fcd6f3779460e81f60815dae56c1c4d9557847501d1c8fa0e813b9f457",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753711860,
      "headline": "RVTY Posts Q2 Earnings & Sales Beat, Raises '25 Sales View",
      "id": 136108678,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "Revvity's second-quarter results showcase strong growth in its Diagnostics business, along with recovery in Life Sciences segmental sales.",
      "url": "https://finnhub.io/api/news?id=ae18b0fcd6f3779460e81f60815dae56c1c4d9557847501d1c8fa0e813b9f457"
    }
  },
  {
    "ts": null,
    "headline": "Will Exome and Genome Growth Boost WGS' Q2 Earnings?",
    "summary": "GeneDx is likely to have experienced a Q2 lift, backed by strong Exome and genome test volumes, new indications and strategic tech moves.",
    "url": "https://finnhub.io/api/news?id=7b2f7f6f0fc029c4ac003542ce412cf6de99025e6cb03e0f881d34cf02b78fd2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753709160,
      "headline": "Will Exome and Genome Growth Boost WGS' Q2 Earnings?",
      "id": 136108553,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "GeneDx is likely to have experienced a Q2 lift, backed by strong Exome and genome test volumes, new indications and strategic tech moves.",
      "url": "https://finnhub.io/api/news?id=7b2f7f6f0fc029c4ac003542ce412cf6de99025e6cb03e0f881d34cf02b78fd2"
    }
  },
  {
    "ts": null,
    "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
    "summary": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.",
    "url": "https://finnhub.io/api/news?id=0582a41092d34e0f018c86e16b14498040d3df62d69e57e1f0ce536c5722ede6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753707602,
      "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
      "id": 136108760,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.",
      "url": "https://finnhub.io/api/news?id=0582a41092d34e0f018c86e16b14498040d3df62d69e57e1f0ce536c5722ede6"
    }
  },
  {
    "ts": null,
    "headline": "IDEXX to Release Q2 Earnings: What's in Store for the Stock?",
    "summary": "IDXX eyes a Q2 earnings jump with CAG growth, global pricing gains, and momentum in water and software segments.",
    "url": "https://finnhub.io/api/news?id=3f69eec4de657c93f38f360839618de854e6fa46f0e32d17e9426a068e56edf1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753703760,
      "headline": "IDEXX to Release Q2 Earnings: What's in Store for the Stock?",
      "id": 136108681,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "IDXX eyes a Q2 earnings jump with CAG growth, global pricing gains, and momentum in water and software segments.",
      "url": "https://finnhub.io/api/news?id=3f69eec4de657c93f38f360839618de854e6fa46f0e32d17e9426a068e56edf1"
    }
  },
  {
    "ts": null,
    "headline": "Cell and Gene Therapy Third-Party Logistics Market Forecast and Company Analysis Report 2025-2033 Featuring Cencora, Cardinal Health, McKesson, EVERSANA, Knipper Health, Arvato, DHL, and Kuehne+Nagel",
    "summary": "The Global Cell and Gene Therapy Third-Party Logistics Market is projected to surge to US$ 20.98 billion by 2033, up from US$ 8.66 billion in 2024, growing at a CAGR of 10.33%. Key growth drivers include technological advancements in cold chain logistics, an increase in clinical studies, and the rise of personalized medicine. The expanding demand for cell and gene therapies necessitates temperature-sensitive logistics solutions. Major players like Cardinal Health and McKesson Corporation are enh",
    "url": "https://finnhub.io/api/news?id=ff0518ff0a44b526d642604bea3c6c0a3de36dc9c8f579281f5d4e9d98fc622d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753700220,
      "headline": "Cell and Gene Therapy Third-Party Logistics Market Forecast and Company Analysis Report 2025-2033 Featuring Cencora, Cardinal Health, McKesson, EVERSANA, Knipper Health, Arvato, DHL, and Kuehne+Nagel",
      "id": 136108492,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "The Global Cell and Gene Therapy Third-Party Logistics Market is projected to surge to US$ 20.98 billion by 2033, up from US$ 8.66 billion in 2024, growing at a CAGR of 10.33%. Key growth drivers include technological advancements in cold chain logistics, an increase in clinical studies, and the rise of personalized medicine. The expanding demand for cell and gene therapies necessitates temperature-sensitive logistics solutions. Major players like Cardinal Health and McKesson Corporation are enh",
      "url": "https://finnhub.io/api/news?id=ff0518ff0a44b526d642604bea3c6c0a3de36dc9c8f579281f5d4e9d98fc622d"
    }
  },
  {
    "ts": null,
    "headline": "Best Dividend Aristocrats For August 2025",
    "summary": "Dividend Aristocrats are outperforming SPY in July but still trail year-to-date. Check out my Promising Aristocrats list here.",
    "url": "https://finnhub.io/api/news?id=830665c984684da2b011aea06a74a0926a66a23d46b32622de0a5dbcf64f981a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753679992,
      "headline": "Best Dividend Aristocrats For August 2025",
      "id": 136105728,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2189040496/image_2189040496.jpg?io=getty-c-w1536",
      "related": "CAH",
      "source": "SeekingAlpha",
      "summary": "Dividend Aristocrats are outperforming SPY in July but still trail year-to-date. Check out my Promising Aristocrats list here.",
      "url": "https://finnhub.io/api/news?id=830665c984684da2b011aea06a74a0926a66a23d46b32622de0a5dbcf64f981a"
    }
  }
]